For personal use only

truscreen

TRUSCREEN GROUP LIMITED

RIGHTS ISSUE OFFER DOCUMENT

1 for 5 renounceable rights offer of ordinary shares

21 **May 2026**



This Offer Document is an important document. You should read the whole document before deciding what action to take with your Rights. If you have any doubts as to what you should do, please consult your broker, financial, investment or other professional advisor. This Offer Document may not be distributed outside New Zealand or Australia.

a world without cervical cancer

CONTENTS

IMPORTANT INFORMATION 3
CHAIRMAN'S LETTER 6
KEY TERMS OF THE OFFER 8
IMPORTANT DATES 10
ACTIONS TO BE TAKEN BY ELIGIBLE SHAREHOLDERS 11
TERMS OF THE OFFER 18
GLOSSARY 24
COMPANY DIRECTORY 25

For personal use only

IMPORTANT INFORMATION

General Information

This Offer Document has been prepared by TruScreen Group Limited (TruScreen) in connection with a one (1) for five (5) renounceable rights offer of New Shares.

The Offer is made to Eligible Shareholders in New Zealand pursuant to the exclusion in clause 19 of schedule 1 of the Financial Markets Conduct Act 2013 *(FMCA)*.

This Offer Document is not a product disclosure statement for the purposes of the FMCA, and does not contain all of the information that an investor would find in a product disclosure statement or which may be required to make an informed decision about the Offer or TruScreen.

The Offer is made to Eligible Shareholders in Australia pursuant to the provisions of the Corporations Act 2001 (Cth) (**Corporations Act**) (as modified by Australian Securities and Investments Commission (**ASIC**) Corporations (Non-Traditional Rights Issues) Instrument 2026/98 (**ASIC Instrument 2026/98**) and ASIC Instrument 23-0122). The Rights will not be quoted on the NZX Main Board or the Australian Securities Exchange (ASX).

This Offer Document is not a prospectus, product disclosure statement or any other formal disclosure document for the purposes of Australian law or the Corporations Act and is not required to, and does not, contain all the information which would be required in a disclosure document under Australian law or the Corporations Act. It may contain references to dollar amounts which are not Australian dollars, may contain financial information which is not prepared in accordance with Australian law or practices, may not address risks associated with investment in foreign currency denominated investments and does not address Australian tax issues. TruScreen is a company which is incorporated in New Zealand and the relationship between it and investors will be largely governed by New Zealand law.

This Offer Document has not been, and will not be, lodged or registered with ASIC and TruScreen is not subject to the continuous disclosure requirements under the Corporations Act or the ASX Listing Rules. TruScreen is only required to comply with the continuous disclosure rules of the NZX Listing Rules.

Prospective investors should not construe anything in this Offer Document as legal, business or tax advice nor as financial product advice for the purposes of Chapter 7 of the Corporations Act.

Additional information available under TruScreen's disclosure obligations

TruScreen is subject to continuous disclosure obligations under the NZX Listing Rules. Further information relating to the Offer can also be found in TruScreen's recent market announcements and its most recent unaudited financial statements for the six-month period ended 30 September 2025, which can be accessed online at www.nzx.com under the ticker code "TRU".

TruScreen may, during the Offer, make additional releases to NZX. To the maximum extent permitted by law, no release by TruScreen to NZX will permit an Applicant to withdraw any previously submitted Application without TruScreen's prior consent.

We encourage you to read this document and to seek investment advice from a suitably qualified professional adviser before you consider investing.

Offering restrictions

This Offer Document is intended for use only in connection with the Offer to Eligible Shareholders. To be an Eligible Shareholder you must be:

For personal use only

- A Shareholder with a registered address in New Zealand; or
- A Shareholder with a registered address in Australia.

This Offer Document does not constitute an offer or invitation in any country in which, or to any person to whom, it would not be lawful to make such an offer or invitation.

This Offer Document may not be sent or given to any person outside New Zealand or Australia. The distribution of this Offer Document (including an electronic copy) outside New Zealand or Australia may be restricted by law. In particular, this Offer Document may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside New Zealand or Australia except as detailed in this Offer Document, or as TruScreen may otherwise determine in compliance with applicable laws.

Neither this Offer Document nor the Application Form may be released or distributed in the United States of America.

No guarantee

No guarantee is provided by any person in relation to the New Shares to be issued under the Offer. Likewise, no warranty is provided about the future performance of TruScreen or any return on any investment made pursuant to this Offer Document. Eligible Shareholders should be aware that there are risks associated with investing in the New Shares. The principal risk is that Eligible Shareholders may not be able to recoup the Issue Price and/or may not receive any dividends, entitlements, or other distributions in respect of the New Shares. In addition, the market for the New Shares may not be liquid. If liquidity is low, Eligible Shareholders may be unable to sell their New Shares at an acceptable price or at all.

Privacy

Any personal information provided in your Application will be held by TruScreen and the Registrar at the addresses set out in the Directory. This information will be used for the purposes of administering your investment in TruScreen and will be disclosed to third parties only with your consent or if required by law. Under the Privacy Act 2020 (New Zealand) you have the right to access and correct any personal information held about you.

Dividend policy

The payment of dividends is at the discretion of the Board. The Board has no present intention to make a distribution for the foreseeable future. This policy may change from time to time at the discretion of the Board in the future.

Decision to participate in the Offer

The information in this Offer Document does not constitute a recommendation to acquire New Shares nor does it amount to financial product advice. This Offer Document has been prepared without taking into account the particular needs or circumstances of any Applicant or investor, including their investment objectives, financial or tax position. Before deciding whether to invest in the New Shares, you must make your own assessment of the risks associated with an investment in TruScreen, and consider whether such an investment in TruScreen is suitable for you having regard to publicly available information about TruScreen, your personal circumstances and following consultation with a financial adviser or other professional adviser.

Forward looking statements

This document contains certain statements that relate to the future. Such forward looking statements are not a guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other factors,

For personal use only

many of which are beyond the control of TruScreen and which may cause the actual results, performance or achievements of TruScreen to differ materially from those expressed or implied by such statements.

Under no circumstances should you regard the inclusion of forward looking statements in this document as a guarantee of future performance.

The statements, although made in good faith, involve known and unknown risks, uncertainties, and assumptions, many of which are beyond the control of TruScreen.

Withdrawal and date changes

Subject to compliance with all applicable laws, TruScreen reserves the right at its absolute discretion to:

- withdraw all or any part of the Offer and the issue of New Shares; and/or
- alter any dates set out in this Offer Document.

Enquiries

Enquiries about the Offer can be directed to an NZX or ASX Firm, an authorised financial advisor, or your solicitor, accountant, or other professional adviser. If you have any questions about the number of New Shares shown on your Entitlement and Acceptance Form, or how to complete the Entitlement and Acceptance Form or online application, please contact the Registrar, whose contact details are set out in the Directory.

Times, currency, and laws

All references in this Offer Document to times and dates are to times and dates in New Zealand. All references in this Offer Document to currency are to New Zealand dollars, and all references to applicable statutes and regulations are references to New Zealand statutes and regulations.

Defined terms

Capitalised terms used in this Offer Document have the meaning given to them in the Glossary in the relevant section of this Offer Document.

For personal use only

For personal use only

CHAIRMAN'S LETTER

Dear fellow shareholder,

On behalf of the directors of TruScreen Group Limited we are pleased to offer Eligible Shareholders the opportunity to participate in a 1 for 5 renounceable rights issue at an issue price of NZ$0.013 per share (A$0.011), to raise up to circa NZ$1.943 million (A$1.644 million). This represents a discount of 24% to the closing price on 19 May 2026. TruScreen has announced today the launch of a private placement of new shares at an issue price of NZ$0.014 (A$0.012) that include a 2 year free attaching option at the exercise price of NZ$0.014 (A$0.012). The lower pricing to shareholders for the Rights Offer ensures valuation parity for both the placement and the Rights Offer.

TruScreen achieved product sales growth of 42% YOY to FY2026, and promisingly through a broader range of participant countries. This included first sales in India with 468 million screening-age women and Indonesia with 95 million of screening age and a government funded mass screening program, representing a runway into significant total addressable markets.

TruScreen is focussed on accelerating new market development, with a more diversified geographic distribution footprint that will provide leverage to improve commercial returns. TruScreen's additional drive to participate in public screening programmes requires investment, but the Board believes that achieving critical scale and meeting clinical need will shorten the pathway to profitability.

TruScreen has recently submitted three proposals to UNITAID for screening programmes across 14 high-burden countries in Africa, Asia-Pacific, and Latin America – addressable market 1Bn women, with potential revenue as a consortium lead for TruScreen of up to US$18.4 million. TruScreen's point-of-care portable AI technology is purpose-built for the settings where cervical cancer kills most, where there are no laboratories, no pathologists, and no patient recall second visit. In addition, TruScreen is a technology partner for two separate global and national NGOs in their grant applications to UNITAID for cervical cancer screening funding. In total, TruScreen is the technology partner in five grant applications to UNITAID.

TruScreen enables primary screening where labs are absent, HPV triage where HPV (including Dalton Bio) is primary, and same-visit complement in screen-and-treat settings. This creates a complementary rather than competitive relationship with HPV expansion.

Funds raised from the rights issue will be used as follows:

MDR Compliance/ regulatory - completion by 2028	NZ$100,000
African market registrations	150,000
Clinical evidence development	200,000
Sales and marketing expansion	200,000
Distributor support programmes	150,000
Manufacturing capacity – replacement tooling	200,000
Working capital	943,000
Total	1,943,000

The TruScreen® Ultra is an AI enabled, primary cervical cancer screening device, at the leading edge of cervical cancer screening, with outstanding results from major clinical trials. TruScreen has a low overhead Australian base, supported by distributors in 15 countries, a manufacturing facility in Australia, and China for devices marketed and sold in China.

Eligible Shareholders are entitled to take up one New Share for every five Existing Shares held. Any Shortfall will be offered to investors through a Shortfall Bookbuild process. Eligible Shareholders who take up their entitlements in full are also able to apply for any Shortfall through the Shortfall Bookbuild.

Any Premium above the Issue Price that is achieved in the Shortfall Bookbuild will be shared between those Shareholders who did not, or were unable to, take up their Rights, in proportion to the number of Rights not taken up.

Eligible Shareholders have until 5:00pm (NZT) on 17 June 2026 to apply for New Shares under the Offer.

Shareholders who choose not to take up their Rights entitlements will have their percentage shareholding diluted, but may receive some value through the Shortfall Bookbuild if a Premium is payable.

This document sets out important information about TruScreen and the Offer. Before making your investment decision, I encourage you to read these documents in full and also to consider the information disclosed by TruScreen to NZX and ASX and other information available at www.nzx.com and www.asx.com.au under the ticker code "TRU".

If you are in doubt as to what you should do, you should consult your financial or professional adviser.

I advise that directors who hold shares in TruScreen intend to take up their full entitlement of Rights.

TruScreen is at an important inflection point of our commercialisation journey. Sales of our Single Use Sensor (SUS) are accelerating with the growing number of our TruScreen® Ultra devices installed in commercial use. The focus of TruScreen on public health screening programmes to assist low- and middle-income countries to achieve their 70% WHO screening target by 31 December 2030 is a significant driver of our commercialisation journey.

I commend this Offer to Eligible Shareholders to enable TruScreen to achieve its growth objectives.

Yours sincerely,



Tony Ho

Chairman

For personal use only

KEY TERMS OF THE OFFER

Issuer	TruScreen Group Limited.
The Offer	A renounceable rights offer of one (1) New Share for every five (5) Existing Shares held on the Record Date (being 5.00pm (NZT), 28 May 2026), with fractional entitlements being rounded down to the nearest share, followed by a Shortfall Bookbuild.
Eligible Shareholders	Shareholders with registered addresses in New Zealand or Australia on the Record Date.
Issue Price	NZ$0.013 or (A$0.011, being the A$ price) per New Share. Any New Shares issued under the Shortfall Bookbuild will be issued at the Bookbuild Price.
Shortfall Bookbuild	Eligible Shareholders who take up their Rights in full have the opportunity to apply for additional New Shares which are attributable to any Rights not taken up. These applications for additional New Shares will go into a Shortfall Bookbuild process which may also involve other investors.
Offer Size	Up to circa NZ$1.943 million (A$1.644 million). In the event that TruScreen receives subscriptions for more than circa NZ$1.943 million under the Offer it reserves the right to issue additional Shares under the 15% placement Listing Rule or in any other manner it may lawfully do so.
Shares currently on issue	747,325,326 Shares quoted on the NZX Main Board.
Maximum number of New Shares being offered	149,465,065 New Shares (subject to rounding, and to TruScreen's right to issue further shares under the Listing Rules).
Rights	Eligible Shareholders have an entitlement to subscribe for one (1) New Share for every five (5) Existing Shares held on the Record Date (5.00pm (NZT), 28 May 2026) at the Issue Price. Eligible Shareholders may take up some, or all, or none of their Rights. If you do not take up all of your Rights, your shareholding percentage in TruScreen will be diluted.
No Rights trading	The Rights will not be quoted on the NZX Main Board or the ASX, and accordingly there will be no established market for Rights. If you wish to sell your Rights privately to a buyer you identify, you should contact the Registrar, MUFG Pension & Market Services (see Directory), to request a Security Renunciation Form.
When to apply	Application (including postal applications) must be received by the Closing Date (5:00pm (NZT) on 17 June 2026, unless extended).
How to apply	An application by an Eligible Shareholder must be made either: • online at https://Truscreen.rightsoffer.co.nz. To complete an online application, you will be required to enter your CSN/Holder number; or • by returning the Entitlement and Acceptance Form and following the payment instructions on that form.

For personal use only

No Underwriting	The Offer is not underwritten.
Dilution	Whilst an Eligible Shareholder is not obliged to participate in the Offer, it is important to note that if an Eligible Shareholder chooses not to participate in the Offer, then their shareholding will be diluted down accordingly.

For personal use only

truscreen®

IMPORTANT DATES

Event	Date
Announcement of the Offer	21 May 2026
Record Date	5.00pm (NZT) / 3.00pm (AEST) on 28 May 2026
Opening Date for the Offer	29 May 2026
Dispatch of Offer Documents and Entitlement and Acceptance Forms	29 May 2026
Closing Date for the Offer	5:00pm (NZT) / 3.00pm (AEST) on 17 June 2026
Shortfall Bookbuild opens	18 June 2026
Shortfall Bookbuild closes	5:00pm (NZT) / 3.00pm (AEST) on 24 June 2026
Announcement of results of the Offer and Shortfall allocation	25 June 2026
Allotment of New Shares, despatch of holder statements and commencement of trading of New Shares	30 June 2026
Payment of any refund from scaling of Offer and/or Shortfall application	by 30 June 2026

The dates above are subject to change and are indicative only. TruScreen reserves the right to amend this timetable (including by extending the Closing Date) subject to applicable laws and the Listing Rules. TruScreen reserves the right to withdraw the Offer at any time at its absolute discretion.

For personal use only

ACTIONS TO BE TAKEN BY ELIGIBLE SHAREHOLDERS

AVAILABLE ACTIONS

If you are an Eligible Shareholder, accompanying this Offer Document is an Entitlement and Acceptance Form showing the number of Rights to subscribe for New Shares that you are entitled to under the Offer. You may take one or more of the following actions:

- take up all or some of your Rights; or
- take up all of your Rights and apply for additional New Shares under the Shortfall Bookbuild (Shortfall Shares); or
- sell all or some of your Rights privately; or
- take up some of your Rights, and sell all or some of the remaining balance privately; or
- do nothing with all of your Rights.

If you do nothing with your Rights before the Closing Date, they will lapse and you will not be able to subscribe for any New Shares under the Offer.

The Offer is an offer to Eligible Shareholders only. If you take up all of your Rights your percentage shareholding in TruScreen will not reduce (subject to TruScreen not issuing additional New Shares in addition to those being offered under this Offer), but if you do not take up all your Rights, your percentage shareholding will reduce following the completion of the Offer. For example, if you hold 5,000 Shares on the Record Date, you will have 1,000 Rights. If you decide not to take up any of your Rights, and all other shareholders do take up their Rights, your percentage interest in TruScreen will be diluted, however, you may receive some value for your Rights under the Shortfall Bookbuild if a Premium is payable.

TAKING UP YOUR ENTITLEMENT

Eligible Shareholders who wish to take up all or some of their Rights must apply online at https://Truscreen.rightsoffer.co.nz in accordance with the instructions set out in their Entitlement and Acceptance Form.

There is no minimum number of New Shares that you must subscribe for under the Offer. Applicants will not be treated as having offered to purchase a greater number of New Shares than the number for which payment is made.

APPLYING TO SUBSCRIBE FOR SHORTFALL SHARES

Eligible Shareholders who wish to apply for Shortfall Shares in addition to their Entitlement may apply for an additional number of New Shares through the Shortfall Bookbuild in excess of the Rights they hold.

Eligible Shareholders may apply for Shortfall Shares in the Shortfall Bookbuild through the online application process on the website for the offer https://Truscreen.rightsoffer.co.nz, provided that the Eligible Shareholder has taken up all of their Rights in full, by applying for a dollar amount of Shortfall Shares where provided on the Application Form. If you do not accept your Rights in full, your Application for any Shortfall Shares will be disregarded.

The number of Shortfall Shares that you may receive under the Shortfall Bookbuild will be determined by TruScreen.

TruScreen may scale applications for Shortfall Shares through the Shortfall Bookbuild, including from Existing Shareholders, in such manner as the directors of TruScreen consider equitable and in the interests of TruScreen. The directors' decision on scaling will be final.

For personal use only

SELLING YOUR ENTITLEMENT

The Rights will not be quoted on the NZX Main Board or the ASX, and accordingly there will be no established market for Rights. If you wish to sell your Rights privately to a buyer you identify, you should contact MUFG Pension & Market Services (see Directory) to request a Security Renunciation Form.

Please note that if the buyer of your Rights is an Ineligible Shareholder or a person that would be an Ineligible Shareholder were they a registered holder of Shares, that buyer will not be able to take up the Rights they have purchased.

Renunciations must be lodged with the Share Registrar, MUFG Pension & Market Services, not later than the Closing Date (5.00pm (NZT) on 17 June 2026). The Share Registrar's details for the return of your Entitlement and Acceptance Form are set out in the Directory.

ACCEPTING SOME OF YOUR ENTITLEMENT

There is no minimum number of New Shares that you must subscribe for under the Offer. You may take up as many or as few of your Rights as you wish. If you wish to take up some of your Rights and sell the balance, you should:

- make arrangements privately to sell the number of Rights you wish to sell or, alternatively, wait for the Shortfall Bookbuild under which you may receive some value for the Rights you do not take up if a Premium is payable; and
- Indicate the number of New Shares you wish to apply for under the Offer online at https://Truscreen.rightsoffer.co.nz in accordance with the instructions set out in your Entitlement and Acceptance Form, and pay for the number of New Shares applied for in accordance with the instructions provided.

If TruScreen receives, on or before the Closing Date (5.00pm (NZT) on 17 June 2026) both an acceptance and a renunciation by an Eligible Shareholder in respect of the same Rights, effect will be given to the renunciation in priority to the acceptance.

YOU MAY ELECT TO DO NOTHING

If you do nothing, your rights will lapse and you will not be able to subscribe for any New Shares. In this case, you may receive some value for your Rights under the Shortfall Bookbuild if a Premium is payable.

HOW TO APPLY FOR NEW SHARES

An application by an Eligible Shareholder must be made:

- online at https://truscreen.rightsoffer.co.nz in accordance with the instructions set out in their Entitlement and Acceptance Form To complete an online application, you will be required to enter your CSN/Holder number; or

If you elect to subscribe for Shortfall Shares through the Shortfall Bookbuild, you must also make payment for both your Rights entitlement, together with the dollar amount that you wish to apply for under the Shortfall Bookbuild.

In the event that all or part of your application for New Shares in the Shortfall Bookbuild is not successful, then TruScreen will refund any extra application monies to you within five Business Days of the Allotment Date.

By completing and returning an Entitlement and Acceptance Form (or completing the online application) and applying for New Shares, you agree to accept the New Shares:

- subject to the terms set out in the constitution of TruScreen; and

For personal use only

- on the terms set out in this Offer Document and the Entitlement and Acceptance Form.

Your application is irrevocable and cannot be withdrawn. TruScreen has the sole discretion to accept or reject your application for New Shares.

PAYMENT

If you are an NZX Shareholder, you must:

- elect to apply using New Zealand dollars at the NZ$ Offer Price; and
- pay for your New Shares by way of direct debit.

If you are an ASX Shareholder, you must:

- elect to apply using Australian dollars at the A$ price; and
- pay for your New Shares by way of BPAY®.

If you are a Custodian (or you hold your Shares through a Custodian), please see Section on Custodians.

Payment must be made for both your Rights and the dollar amount of additional New Shares that you are applying for under the Shortfall (if any).

If any scaling is applied to the application for Shortfall Shares under the Shortfall Bookbuild, a refund of any extra application monies will be processed within five Business Days of the Allotment Date. Refunds will not be paid for any difference arising solely due to rounding or where the aggregate amount of the refund payable to you is less than NZ$5.00.

ENQUIRIES

If you have any queries about the number of Rights shown on the Entitlement and Acceptance Form please contact the Share Registrar via email at applications.nz@cm.mpms.mufg.cpm or phone +64 9 375 5998.

For personal use only

OVERVIEW OF TRUSCREEN GROUP LIMITED

OVERVIEW

TruScreen Group Limited is listed on the NZX Main Board. TruScreen is also dual listed on the ASX as a Foreign Exempt Listing.

NATURE OF TRUSCREEN'S OPERATIONS AND MAIN ACTIVITIES OF THE TRUSCREEN GROUP

Who is TruScreen

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that has developed and commercialises an AI-enabled medical device for detecting pre-cancerous and cancerous cell abnormalities in the cervix in real-time via measurements of the low level optical and electrical stimuli responses.

TruScreen's cervical cancer screening technology enables cervical screening **without collecting tissue and processing of tissues in laboratories, providing immediate result, at the point of care**. The technology avoids patient's discomfort, failed samples, missed follow-up, and the need for costly, specialised personnel and expensive laboratory infrastructure. TruScreen works closely with global and national NGOs (Non-Government Organisations) and with a network of international distributors. It enables TruScreen to hold intellectual property in Australia and New Zealand while maximising the commercial outreach globally. The distributors hold the local knowledge and manage the relationships with diverse stakeholders. The key revenue stream comes from the **disposable consumable, Single Use Sensor (SUS), used only once for each examination with TruScreen® Ultra device.**

The TruScreen device, TruScreen ® Ultra, is a class 2a medical device, registered as a primary screening tool for cervical cancer. The device is EU certified (CE Mark), ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), WAND (New Zealand), IEAKI (Indonesia), HSA (Singapore), Thai FDA (Thailand), Centre for Pharmaceutical Products Safety of Uzbekistan and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Zimbabwe, Rwanda among others and has active distributors in 20 countries. Registrations are pending in India, South Africa, Belarus, Kyrgyzstan and Malaysia.

In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China as a domestic, Made In China medical device, enabling TruScreen to participate in government screening programs and tenders. China remains TruScreen's largest market, accounting for 62% of its sales in FY2026, as well as the market with the highest growth potential with up to 404m women of addressable screening age.

In 2023, the technology has been endorsed and recognised by the China Obstetricians and Gynaecologists Association (COGA) in a China Blue Book "Cervical Cancer Three Stage Standardized Prevent and Treatment" that was published by them in collaboration with 5 other government associations, and was also included in the CSCCP (Chinese Society of Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

In 2024, TruScreen was Included in the Russian National Cervical Cancer Screening Guideline. TruScreen was added to the Vietnamese MoH Technical List in 2023, the prerequisite for a medical product to be used in the public sector. These important milestone national guidelines were based on independently generated body of evidence supporting TruScreen clinical use world-wide and after extensive consultations with healthcare practitioners and decision makers.

In FY2026 alone, over 160,000 units of SUS were sold world-wide. By the end of 2026 financial year, over 300 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, Indonesia, Jordan, Rwanda, and Saudi Arabia.

TruScreen's vision is "A world without cervical cancer". In 2019, World Health Organisation (WHO) launched a strategy to eliminate cervical cancer as the first ever cancer from humanity by the end of this century. To date, over 150 countries

For personal use only

have committed to the WHO targets. The WHO strategy comprises a target for screening of eligible women, and TruScreen provides a solution to many countries that are struggling to reduce the mortality from one of the biggest killer diseases of women world-wide. Some 350,000 women died from cervical cancer annually, with 70% of deaths from low and middle income countries.

In November 2020, WHO issued the 90-70-90 milestone targets to be achieved by December 2030 for its member nations. That is, 90% of girls to be vaccinated against HPV by age 15, 70% of woman to be screened by age 35 and again by age 45, 90% of women identified with cervical pre-cancer or invasive cervical cancer receive proper treatment or management. The compressed dateline from now to end of 2030 has created a greater sense of urgency for member nations to implement public health screening programmes to achieve those targets. With no requirements for laboratory or pathology infrastructure, TruScreen's portability and real time screening technology is ideally suited for the low and middle income countries. This provides a 3+ year time window for TruScreen to assist these countries to achieve their 70% screening milestones.

In April 2026 TruScreen announced it had submitted three proposals for screening programmes across 14 high-burden countries in Africa, Asia-Pacific, and Latin America – addressable market 1Bn women. The programmes seek to achieve WHO's 90-70-90 milestones over a 36 month period to December 2030, with funding up to US$57.3 million over the three-year period with potential revenue as a consortium lead for TruScreen of up to US$18.4 million. These submissions followed TruScreen's success with the National Aids Council programme in Zimbabwe, where over 30,000 women were screened by TruScreen, and in early this year, the programme was extended by Zimbabwe MoH nationally. TruScreen has also partnered with two global and national NGOs in their separate grant application to UNITAID for cervical screening programmes. In total, TruScreen is the technology partner in five grant applications to UNITAID.

Successful applicants to be advised on or around November 2026.

To learn more, please visit: www.truscreen.com

Our Strategy

TruScreen seeks to further develop and expand its sales and distribution channels to increase sales of its medical device and its consumable SUS in its targeted and new markets. Several initiatives to improve financial performance are in place. TruScreen has the following short-term strategy:

Focus on public health screening programmes – provides a much broader rapid coverage. Vietnam launched a 5 year programme to screen 260,000 women in April 2025.

Pivot to screen and treat model in line with WHO's updated 2021 guidelines – TruScreen + Rapid HPV DNA test +thermal ablation

NGO engagement – Global and Multi-Country Organisations – eg Unitaid and PATH

Expand to new high Total Addressable Markets – India, Indonesia, Nigeria and South Africa

Working closely with its exclusive SUS manufacturer to reduce SUS and logistic costs for margin improvements.

Recent Milestones

In FY2026, TruScreen broadened its revenue base to include India and Indonesia, in addition to existing established markets in China, Vietnam, Zimbabwe, Central Asia and Mexico. Truscreen also signed new distributor agreement in South Africa. Pending new distributors to be appointed include, Uzbekistan, Nigeria, Romania and Bangladesh.

TruScreen's success with the National Aids Council programme in Zimbabwe resulted in the TruScreen being approached by global aid national agencies to submit applications to assist in the achievement of WHO's cervical cancer elimination goals. TruScreen submitted three proposals developed in partnership with leading global and national health organisations, to present a comprehensive programme to deploy TruScreen's portable AI-enabled opto-electronic cervical screening technology across 14 high-burden countries in Africa, Asia-Pacific, and Latin America

For personal use only

with an addressable market of one billion women of screening age.

More recently, TruScreen collaborated with Nigeria's Lagos State University Teaching Hospital (LASUTH) in a grant application to Gates Foundation and United Nations Population Fund (UNFPA), for a Dalton HPV study in Nigeria.

TruScreen received further recognition during the year as a primary AI cervical cancer screening solution. A 297-patient study published and peer review in Journal of Sichuan University found that TruScreen combined with hr HPV testing confirmed superior performance in cervical cancer screening compared with Thinprep cytology test (TCT) combined with hr HPV test.

This publication adds to TruScreen's expanding clinical evidence base, which now comprises more than 30 trials and large studies involving over 40,000 women worldwide. The findings are consistent with the TruScreen's larger clinical evaluations, including the landmark COGA study of 14,982 women – the world's largest opto-electronic cervical cancer screening study - published in February 2026 in Germany's BMC Cancer and confirming TruScreen's superiority as a primary screening tool compared with liquid based cytology and hr HPV testing.

A new study published in the leading Chinese medical publication *Family Doctor,* validated TruScreen's efficacy as an initial screening tool for cervical lesions during pregnancy. This is the first study to focus on TruScreen's use in pregnancy. The study can be viewed at https://www.cnki-acc.net/wenzhang/37126.html (in Chinese).

What's Next for TruScreen

Longer term, TruScreen will:

- Expand its existing market presence to new, large population markets in Africa, Latin America, and others;
- Add new healthcare products and services to its portfolio, to encompass the wider women's health category in reproductive diseases; and
- Expand application for the technology in screening for diverse range of cancers.

People

The TruScreen team have a wealth of experience in medical devices and market experience. For further details see https://www.truscreen.com/news-announcements

Further Resources

Scientific publications 2020-2026:

- Chen F, Chen W, Liu J, Wang J, Guo H, Zhang G, Zhang Y, Yang Q, Zhao R, Chen X, Cui M, Zhao W, Liu J, Liou YL, Lang J. A real-world multicenter study on opportunistic cervical cancer screening in hospital in China: comparison of TruScreen device, cytology, and HPV testing for detecting high-grade cervical lesions. BMC Cancer. 2026 Feb 4. doi:10.1186/s12885-026-15590-6. Available from: https://pubmed.ncbi.nlm.nih.gov/41634646/
- Gao, S., Tian, Y., Song, F., & Wang, J. (2025). Assessment of the real-time photoelectric detection device (TruScreen) in screening for cervical precancerous lesions in middle-aged women: An observational study. Risk Management and Healthcare Policy, 18, 1783–1791.
- Xiao, F., & Sui, L. (2024). Evaluation of a real-time optoelectronic method for the detection of cervical intraepithelial neoplasia and cervical cancer in patients with different transformation zone types. Scientific Reports, 14, Article 27220.
- Xiao, F., & Sui, L. (2024). Evaluation of a real-time optoelectronic method for the detection of cervical

For personal use only

intraepithelial neoplasia and cervical cancer in patients with different transformation zone types. Scientific Reports, 14, 27220.

- Yang Y, et al. Optimal Screening and Detection Strategies for Cervical Lesions: A Retrospective Study. Journal of Cancer 2024, Vol. 15
- Liu, H et al. Study on the role of TruScreen Screening Technology in Cervical Cancer Screening. Reproductive Medicine Journal August 2023 Vol 32, No 8
- Luo, L et al. The Value of TruScreen (An Artificial Intelligence Cervical Cancer Screening System) in High-Risk HPV Positive Patients. Clin. Exp. Obstet. Gynecol. 2023; 50(10): 206
- Chen, Z et al. The clinical value of TruScreen in cervical cancer screening. Shangdong Med 2022 Vol 6 No 22
- Zhu B et al. A comparative study of photoelectric screening system Truscreen and colposcopy in cervical lesions screening. CHINESE JOU R NAL OF FAMILY PLANNING & GYNECOTOKOLOGY Volume 14 Number 11 2022
- Zhao, Y et al. Accuracy of TruScreen in the Early Diagnosis of Cervical Precancerous Lesions in Outpatients in Sichuan Province. J Cancer Control Treat. February 2022, Vol. 35, No. 2
- Jessica N Vet et al., A Performance Evaluation of an Optoelectronic Cervical Screening Device in Comparison to Cytology and HPV DNA Testing, Eur. J. Gynaecol. Oncol. 2022; 43(2): 213–218 http://doi.org/10.31083/j.ejgo4302027
- Y. Wei, W. Wang, M. Cheng et al., Clinical evaluation of a real-time optoelectronic device in cervical cancer screening, European Journal of Obstetrics & Gynaecology and Reproductive Biology, https://doi.org/10.1016/j.ejogrb.2021.09.027
- Comparison of the detection rate of cervical lesion with TruScreen, LBC test and HPV test: A Real-world study based on population screening of cervical cancer in rural areas of China, Yu Ma, Jiangli Di , Hui Bi, et al., https://doi.org/10.1371/journal.pone.0233986

For personal use only

TERMS OF THE OFFER

THE OFFER

The Offer is an offer of New Shares in TruScreen to Eligible Shareholders under a pro-rata renounceable rights issue, followed by a Shortfall Bookbuild. Under the Offer, Eligible Shareholders are entitled to subscribe for one (1) New Share for every five (5) Existing Shares held on the Record Date. Any fractional Entitlements will be rounded down to the nearest whole number.

The New Shares will be of the same class as, and rank equally with, the Existing Shares which are quoted on the NZX Main Board and the ASX. It is a term of the Offer that TruScreen will take any necessary steps to ensure that the New Shares are quoted immediately after the issue.

Eligible Shareholders who take up their Rights in full may also apply for additional Shortfall Shares under the Shortfall Bookbuild.

The maximum number of New Shares being offered under the Offer is 149,465,065 New Shares.

ISSUE PRICE AND APPLICATION MONIES

The Issue Price under the Offer is NZ$0.013 (A$0.011) per New Share. The A$ price has been set by TruScreen taking into account the A$:NZ$ exchange rate published by the Reserve Bank of New Zealand on its website at 5pm on 30 April 2026.

Payment for the New Shares (together with any additional Shortfall Shares applied for) must be made in full in accordance with the instructions set out in the Entitlement and Acceptance Form. If you are an NZX Shareholder, you must elect to apply using New Zealand dollars at the NZ$ price. If you are an ASX Shareholder, you must elect to apply using Australian dollars at the A$ price.

TruScreen may (at its discretion) accept late applications and Application Monies, but has no obligation to do so. TruScreen may accept or reject (at its discretion) any Entitlement and Acceptance Form which it considers is not completed correctly, and may correct any errors or omissions on any Entitlement and Acceptance Form.

If an Eligible Shareholder does not renounce their Rights and does not apply for any New Shares and pay the associated Application Monies by the Closing Date (5.00pm (NZT) on 17 June 2026), their Rights will lapse.

Application Monies received will be held in a trust account with the Share Registrar until the corresponding New Shares are allotted or the Application Monies are refunded. Interest earned on the Application Monies will be for the benefit, and remain the property, of TruScreen and will be retained by TruScreen whether or not the issue and allotment of New Shares takes place.

Any refunds of Application Monies will be made within five Business Days of allotment, or, if a decision is made not to proceed with the Offer, within five Business Days of the date of that decision.

Once submitted, and subject to all applicable law, an Application is irrevocable and cannot be withdrawn.

ELIGIBILITY

The Offer is only open to Eligible Shareholders or persons that TruScreen is satisfied can otherwise participate in the Offer in compliance with all applicable laws.

TruScreen considers that the legal requirements of jurisdictions other than New Zealand and Australia are such that it would be unduly onerous for TruScreen to make the Offer in those jurisdictions. This decision was made having regard

For personal use only

to the small number of Shareholders in such overseas jurisdictions, the financial resources of TruScreen and the costs of complying with overseas legal requirements.

This Offer Document is intended for use only in connection with the Offer to any person recorded in TruScreen's share register as a Shareholder on the Record Date (5.00pm (NZT) 28 May 2026):

- whose address is shown in TruScreen's share register as being in New Zealand; or
- whose address is shown in TruScreen's share register as being in Australia.

This Offer Document is not to be sent or given to any person outside New Zealand or Australia in circumstances in which the Offer or distribution of this Offer Document would be unlawful.

OPENING AND CLOSING DATES

The Offer will open for receipt of acceptances from 29 May 2026 (**Opening Date**). The last day for receipt of the completed Acceptance and Entitlement Form with payment is 5.00pm (NZT) on 17 June 2026 (**Closing Date**), subject to TruScreen varying those dates in accordance with the Listing Rules.

NO RIGHTS TRADING

The Rights will not be quoted on the NZX Main Board or the ASX, and accordingly there will be no established market for Rights. If you wish to sell your Rights privately to a buyer you identify, you should contact the Registrar, MUFG pension & Market Services (see Directory), to request a Security Renunciation Form.

Please note that if the buyer of your Rights is an Ineligible Shareholder or a person that would be an Ineligible Shareholder were they a registered holder of Shares, that buyer will not be able to take up the Rights they have purchased.

APPLING FOR SHORTFALL SHARES

Eligible Shareholders who take up all of their Rights are entitled to apply for Shortfall Shares under the Shortfall Bookbuild.

Any New Shares in respect of which Rights are not taken up will form the Shortfall and will be available to Applicants who subscribe for New Shares in addition to their Entitlement, as well as other investors. Accordingly, Applicants may apply for additional New Shares in excess of the Rights they hold, subject to the resulting availability.

TruScreen reserves the right to determine who, other than Eligible Shareholders, may participate in the Shortfall Bookbuild and may decline or scale applications for New Shares by any Eligible Shareholder.

Eligible Shareholders who wish to participate in the Shortfall Bookbuild may do so, provided they have fully taken up all of their Rights by:

- in the case of NZX Shareholders, specifying the NZ$ amount of New Shares they wish to apply for on the Entitlement and Acceptance Form where provided; or
- in the case of ASX Shareholders, specifying the A$ amount of New Shares they wish to apply for on the Entitlement and Acceptance Form where provided,

and must pay that NZ$ or A$ amount of additional New Shares being applied for under the Shortfall in addition to their Application Monies for their Rights.

For personal use only

SHORTFALL BOOKBUILD

New Shares attributable to the Shortfall will be offered to Eligible Shareholders who take up their Rights in full, and other investors, under the Shortfall Bookbuild. If you do not take up your Rights under the Rights Offer or are an Ineligible Shareholder, the New Shares attributable to your Shortfall will be offered for sale in the Shortfall Bookbuild.

Shortfall Bookbuild process

Eligible Shareholders that take up their Rights in full can apply for New Shares by specifying the dollar value of New Shares for which you wish to apply at the time you complete and return the Entitlement and Acceptance Form to exercise your Rights. The price at which the New Shares will be issued to Eligible Shareholders is the Bookbuild Price to be set as described below.

Other investors participating in the Shortfall Bookbuild may bid for New Shares equal in number to the Shortfall. The minimum bid that may be submitted for a New Share under the Shortfall Bookbuild is the Issue Price of NZ$0.013 per New Share and this amount is payable to TruScreen.

The Bookbuild Price will be determined by TruScreen and will be:

- no less than the Issue Price; and
- no more than the closing price on the NZX Main Board for an Existing Share as at the close of trading on the day prior to the Shortfall Bookbuild (unless the closing price is less than the Issue Price, in which case the Bookbuild Price will be equal to the Issue Price).

The Bookbuild Price will be set in NZ$ and then converted to A$ at the prevailing exchange rate available to Truscreen at the time the price is set. The proceeds from each New Share issued under the Shortfall Bookbuild (if any) will be paid by the Share Registrar as follows:

- the Issue Price of NZ$0.013 to TruScreen; and
- any Premium achieved to the holders of unexercised Rights (including Ineligible Shareholders) in proportion to their holdings of unexercised Rights. Ineligible Shareholders will be deemed to hold the number of Rights they would have received if they were Eligible Shareholders for the purpose of calculating the amount of any Premium payable to them.

Example

This example assumes that there is demand for all of the New Shares available under the Shortfall Bookbuild and that the Bookbuild Price exceeds the Issue Price.

Issue Price per New Share:	$0.013
Bookbuild Price per New Share:	$0.02
Premium:	$0.007

In this example, a Shareholder who holds 50,000 Existing Shares at 5.00pm on the Record Date who is either an Ineligible Shareholder or is an Eligible Shareholder who chooses not to take up any of his or her Rights will have 10,000 unexercised Rights. That Shareholder will receive $70 in aggregate for his or her unexercised Rights in the Shortfall Bookbuild, being the Premium of $0.007 multiplied by the number of unexercised Rights held by him or her.

The above is an example only. There is no guarantee that the Bookbuild Price will exceed the Issue Price.

If the Bookbuild Price is equal to the Issue Price, there will be no Premium payable to the holders of unexercised Rights.

For personal use only

Application to participate in Shortfall Bookbuild

If you are an Eligible Shareholder and you have taken up all of your Rights, you may participate in the Shortfall Bookbuild by applying online in accordance with the instructions on your Entitlement and Acceptance Form, and applying for a dollar amount of New Shares at the Bookbuild Price.

If you are an investor who is not an Eligible Shareholder, you may participate in the Shortfall Bookbuild by contacting TruScreen at **info@truscreen.com** who will provide details as to the process to be undertaken in relation to the Shortfall Bookbuild. Participation in the Shortfall Bookbuild will be limited to Eligible Shareholders and such other investors in New Zealand and other jurisdictions who TruScreen is satisfied may participate in the Shortfall Bookbuild under all applicable laws without the need for any registration, lodgement or other formality (other than a formality with which TruScreen is willing to comply)

Shortfall Bookbuild allocation policy

Allocations and any necessary scaling of applications for New Shares under the Shortfall Bookbuild will be determined by TruScreen in its discretion. The allocation policy will be influenced by, but not constrained by factors such as:

- the number of New Shares bid for by particular bidders;
- the timeliness of the bid by particular bidders with a likely preference for early bids;
- the price at which the bid is made, with a preference for bids in excess of the Issue Price and demonstration of price leadership;
- the prospects of success of the Offer; and
- any other factors that TruScreen considers appropriate.

Once the Bookbuild Price has been determined, the application monies in respect of any applications for New Shares through the Shortfall Bookbuild by Eligible Shareholders will be divided by the Bookbuild Price to calculate the number of New Shares that those Eligible Shareholders have applied for, rounded down to the nearest whole New Share. Any refunds of application monies due to scaling of applications or applications not being accepted under the Shortfall Bookbuild will be made within five business days (as defined in the Listing Rules) of allotment (without interest).

Payment of Premium

The Premium, if any, will be paid by the Share Registrar in New Zealand or Australian dollars in accordance with the direct credit payment instructions provided by the relevant Shareholder to TruScreen (if any). No interest will be paid in respect of any Premium payable. Payment (if any) is expected to be made by 30 June 2026.

ALLOTMENT OF NEW SHARES

New Shares issued pursuant to the exercise of Entitlements or under the Shortfall are expected to be allotted and issued by 30 June 2026 (**Allotment Date**). Transaction statements confirming the allotment of your New Shares will be issued and mailed in accordance with the Listing Rules.

QUOTATION OF NEW SHARES

The New Shares have been accepted for quotation by NZX and will be quoted upon completion of allotment procedures. The NZX Main Board is a licensed market operated by NZX, which is a licensed market operator regulated under the FMCA. An application will also be made by TruScreen for the New Shares to be issued under the Offer to be quoted on ASX.

For personal use only

However, neither NZX nor ASX accepts responsibility for any statement in this Offer Document. The fact that ASX may approve the New Shares for quotation is not to be taken in any way as an indication of the merits of TruScreen.

CUSTODIANS

Under the Offer, a custodian (**Custodian**) is any Eligible Shareholder having a registered address in New Zealand or Australia, that:

(a) is a trustee corporation or a nominee company and holds Shares in TruScreen by reason only of acting for another person in the ordinary course of business of that trustee corporation or nominee company; or

(b) holds Shares in TruScreen by reason only of being a bare trustee of a trust to which the Shares are subject.

Custodians must confirm to TruScreen that they are holding Existing Shares as a Custodian for one or more beneficial owners (**Participating Beneficiary**) and certify the matters described below by email, together with the Custodian's schedule and make payment by way of electronic funds transfer.

(a) the number of Participating Beneficiaries and their names and addresses;

(b) in respect of each of the Participating Beneficiaries;

(i) the number of Existing Shares that the Custodian holds on behalf of each Participating Beneficiary and the number and dollar amount of Rights; and

(ii) the dollar amount of any additional New Shares in the Shortfall (if eligible),

that each Participating Beneficiary has instructed the Custodian, either directly or indirectly through a Downstream Custodian, to apply for on their behalf;

(c) that a copy of this document was given to each Participating Beneficiary; and

(d) where the Custodian holds Shares on behalf of a Participating Beneficiary indirectly, through one or more Downstream Custodians, the name and address of each Downstream Custodian.

Custodians may not distribute this Offer Document to any person in any country outside New Zealand and Australia.

TERMS AND RANKING OF NEW SHARES

New Shares allotted and issued will be fully paid and will be the same class as, and rank equally in all respects with, Existing Shares on issue that are quoted on the Main Board on the Allotment Date. They will give the holder the right to one vote on a resolution at a meeting of Shareholders (subject to any restrictions in TruScreen's constitution or the Listing Rules), the right to dividends authorised by the Board and the right to a proportionate share in any distribution of surplus assets of TruScreen on any liquidation. Applicants for New Shares will be bound by TruScreen's constitution and the terms of the Offer set out in this Offer Document.

NO MINIMUM AMOUNT TO BE RAISED

There is no minimum amount that must be raised for the Offer to proceed.

AMENDMENTS TO THE OFFER AND WAIVER OF COMPLIANCE

For personal use only

Notwithstanding any other term or condition of the Offer, TruScreen may at its discretion:

- make non-material modifications to the Offer on such terms and conditions as it sees fit (in which event applications for Shares under the Offer will remain binding on the Applicant notwithstanding such modification and irrespective of whether an application was received by the Registrar before or after such modification is made); and/or
- suspend or terminate the Offer at any time prior to the issue of the New Shares under the Offer (including by reviewing the timetable for the Offer). If the Offer is terminated, application monies will be refunded to Applicants without interest within 5 Business Days of termination.

TruScreen reserves the right to waive compliance with any provision of these terms and conditions.

TruScreen will notify NZX and ASX of any waiver, amendment, variation, suspension, withdrawal or termination of the Offer.

BROKERAGE

No brokerage is payable by Eligible Shareholders who accept their Entitlement.

GOVERNING LAW

This Offer Document, the Offer and any contract resulting from it are governed by the laws of New Zealand, and each Applicant submits to the exclusive jurisdiction of the courts of New Zealand.

For personal use only

GLOSSARY

Allotment Date	means the date for allotment of New Shares under the Offer, expected to be on or about 30 June 2026.
Applicant	means an investor whose application for New Shares has been received by the Registrar.
Application	means an application to subscribe for New Shares under this Offer Document.
Application Monies	means monies received from Applicants in respect of their Applications.
ASIC	means the Australian Securities and Investments Commission.
ASX	means ASX Limited or the Australian Securities Exchange operated by ASX Limited, as the context may require.
ASX Shareholder	means an Eligible Shareholder whose Existing Shares are held on TruScreen's ASX branch register on the Record Date.
Board	means the board of directors of TruScreen.
Bookbuild Price	The price per New Share determined by TruScreen through the Shortfall Bookbuild process based on the bids received.
Business Day	has the meaning given to that term in the Listing Rules.
Closing Date	means 5:00pm (NZT) on 17 June 2026.
Eligible Shareholder	means a Shareholder who as at the Record Date is registered as a Shareholder, and has a registered address in New Zealand or Australia.
Entitlement	means the number of Rights to which Eligible Shareholders are entitled.
Entitlement and Acceptance Form	means the personalised entitlement and acceptance form accompanying this Offer Document for Eligible Shareholders.
Existing Share	means a Share on issue on the Record Date.
Ineligible Shareholders	means Shareholders other than Eligible Shareholders.
Issue Price	means NZ$0.013 (A$0.011) per New Share.
Listing Rules	means the NZX Listing Rules.
Main Board	means the NZX Main Board.
New Share	means an ordinary share in TruScreen offered under the Offer of the same class as (and ranking equally in all respects with) Existing Shares at the time of allotment of the New Shares.
NZX	means NZX Limited.
NZX Firm	means an entity designated as an NZX Firm under the Participant Rules of NZX.
NZX Shareholder	means an Eligible Shareholder whose Existing Shares are held on TruScreen's NZX branch register on the Record Date.
Offer	means the offer of New Shares to Eligible Shareholders as at the Record Date, under the renounceable rights offer set out in this Offer Document, together with the Shortfall Bookbuild.
Offer Document	means this document.
Opening Date	means 29 May 2026.
Premium	The amount per New Share, if any, by which the Bookbuild Price exceeds the Issue Price.
Record Date	means 5:00pm (NZT) on 28 May 2026.
Registrar or Share Registrar	means MUFG Pension & Market Services Limited, Auckland.
Right	means the renounceable right to subscribe for one (1) New Share for every five (5) Existing Shares held on the Record Date at the Issue Price, issued pursuant to the Offer.
Share	means one fully paid ordinary share in TruScreen.
Shareholder	means a registered holder of Shares on issue.
Shortfall	means the number of Rights not exercised by Shareholders.
Shortfall Shares	means New Shares available under the Shortfall Bookbuild
Shortfall Bookbuild	The bookbuild process a number of New Shares equal to the Shortfall.
TruScreen	means TruScreen Group Limited.

For personal use only

COMPANY DIRECTORY

ISSUER

TruScreen Group Limited

c/- HLB Mann Judd Limited

Level 6, Equitable House

57 Symonds Street, Grafton

Auckland, 1010

New Zealand

T: +64 9 303 2243

E: hlb@hlb.co.nz

DIRECTORS OF TRUSCREEN GROUP LIMITED

Anthony Ho (Chairman)

Dr. Dexter Cheung

Christopher Horn

Christine Pears

EXECUTIVE MANAGEMENT

Martin Dillon (CEO)

Guy Robertson (CFO)

REGISTRAR

New Zealand

MUFG Pension & Market Services (NZ) Limited

Level 30, PwC Tower

15 Customs Street west

Auckland 1010

New Zealand

PO Box 91976

Victoria Street West

Auckland 1142

New Zealand

For personal use only

Australia

MUFG Corporate Markets (AU) Limited
Liberty Place
Level 41, 161 Castlereagh Street
Sydney NSW 2000

Locked Bag A14
Sydney South NSW 1235

T: + 64 9 375 5998

W: New Zealand - nz.investorcentre.mpms.mufg.com

W: Australia - au.investorcentre.mpms.mufg.com

E: applications.nz@cm.mpms.mufg.com

LEGAL ADVISORS

New Zealand legal advisor:

Russell McVeagh

Level 30, 48 Shortland Street

Auckland 1010

www.russellmcveagh.com

Australian legal advisor:

Addisons

Level 10, 2 Park Street

Sydney NSW 2000

www.addisons.com

For personal use only

truscreen®